Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Your Profits Grow Sky High.

APEIRON Biologics given green light for market approval

Hans Loibner, Apeiron CEO © Apeiron

The development of dinutuximab beta originally began at the Clinical Cancer Research Institute of St. Anna Children’s Hospital in Vienna and was extended to encompass numerous clinical studies throughout Europe and abroad.

In 2011, Apeiron acquired commercial rights to the project, and then led efforts to win market approval in cooperation with academic groups. More than 1,000 patients have been treated up until now. In September 2016, Apeiron EUSA Pharma acquired an exclusive license to the global commercial rights to dinutuximab beta.

The CHMP recommendation issued on March 24, 2017 will be presented to the European Commission by the EMA. The European Commission will issue a formal decision on the approval of dinutuximab beta within the next two months.

Neuroblastoma is the third most frequent malignant tumor afflicting children. The tumors arise from cells of so-called autonomic nervous system. The apparent cause is that cells do not sufficiently mature in their development phase and then begin to reproduce themselves later in an unrestrained manner. About one out of every 5,000 children suffers from this illness. One third of the tumors already occur in children’s first year.

 

About APEIRON Biologics AG

Apeiron is a private biotech company in Vienna, Austria developing innovative projects in the field of immune-oncology..

For more information: www.apeiron-biologics.com

 

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Doing business in Austria

    20.11.2018, Žilina, Slovakia

  • Meet us at: Go Tech Arena Forum

    20.11.2018, Moscow, Russia

Austria Map

Find the perfect location for your company

Austria is well known for its social stability and excellent labor relations where strikes are measured only in seconds. As a global player, reliable deliveries are a top priority for us.

Opel Austria

Logo
More testimonials

news from the business location Austria

Med University of Graz: New center for metabolism research

The kick-off for the Integrative Metabolism Research Center at the Medical University of Graz took place.

Startup Hotspot Austria

The Austrian government expects its Land of Founders strategy to enhance the entrepreneurial spirit and the courage to set up companies. The objective is to transform Austria into the most founder-friendly country in Europe. The initiatives have already borne fruit. The startup scene in Austria has been experiencing a strong boom over years now.

More news All blog posts